CAPRELSA (vandetanib) tablets 300mg

CAPRELSA

Facts of CAPRELSA (vandetanib) tablets 300mg ?

• Medicine Name: CAPRELSA
• Generic Name: Vandetanib
• Approval Date: Feb 21, 2012
• Company Name: AstraZeneca Pharmaceuticals LP
• Available as (Form & Strength): 100 mg and 300mg tablets

What are the indications and usage?

• CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
• Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.